Patient
SITE015-0184
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE015 (POL) (Dr. Ito)
consented 2026-04-12
Adverse events
6
Serious AEs
0
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 6
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-02-25 (study day 130); relationship: not assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-01-16 (study day 90); relationship: not assessed
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-12-27 (study day 70); relationship: not assessed
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-12-25 (study day 68); relationship: not assessed
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-11-30 (study day 43); relationship: NOT RELATED
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-10-21 (study day 3); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.